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Abstract
Introduction: The pan-HDAC inhibitor (HDACI) suberoylanilide hydroxamic acid (SAHA) has previously shown to
be a radio-sensitizer to conventional photon radiotherapy (XRT) in pediatric sarcoma cell lines. Here, we investigate
its effect on the response of two sarcoma cell lines and a normal tissue cell line to heavy ion irradiation (HIT).
Materials and methods: Clonogenic assays after different doses of heavy ions were performed. DNA damage and
repair were evaluated by measuring gH2AX via flow-cytometry. Apoptosis and cell cycle analysis were also
measured via flow cytometry. Protein expression of repair proteins, p53 and p21 were measured using immunoblot
analysis. Changes of nuclear architecture after treatment with SAHA and HIT were observed in one of the sarcoma
cell lines via light microscopy after staining towards chromatin and gH2AX.
Results: Corresponding with previously reported photon data, SAHA lead to an increase of sensitivity to heavy ions
along with an increase of DSB and apoptosis in the two sarcoma cell lines. In contrast, in the osteoblast cell line
(hFOB 1.19), the combination of SAHA and HIT showed a significant radio-protective effect. Laser scanning
microscopy revealed no significant morphologic changes after HIT compared to the combined treatment with
SAHA. Immunoblot analysis revealed no significant up or down regulation of p53. However, p21 was significantly
increased by SAHA and combination treatment as compared to HIT only in the two sarcoma cell lines - again in
contrast to the osteoblast cell line. Changes in the repair kinetics of DSB p53-independent apoptosis with p21
involvement may be part of the underlying mechanisms for radio-sensitization by SAHA.
Conclusion: Our in vitro data suggest an increase of the therapeutic ratio by the combination of SAHA with HIT in
infantile sarcoma cell lines.
Keywords: Infantile sarcoma, histone deacetylase inhibition, heavy ion radiotherapy, suberoylanilide hydroxamic
acid, SAHA
Introduction
HDAC inhibitors (HDACI) induce growth arrest and
affect cell differentiation, apoptosis and anti-angiogenic
effects in tumor cells by chromatin modification with
both transcription-dependent and independent mechan-
isms implicated [1,2].
Suberoylanilide hydroxamic acid (SAHA) is the first
HDACI that has been approved in the United States by
the Food and Drug Administration (FDA) for the treat-
ment of relapsed and refractory cutaneous T-cell lym-
phoma. It has also shown promising preclinical results in
vitro and in vivo for several other cancer types [3-5].
Interesting selective synergistic effects by combination of
SAHA with other cytotoxic agents, amongst others radia-
tion, have been reported for osteosarcoma cells [6,7] as
well as for many other types of cancer cells [8-10].
In a previous report, we have shown that SAHA
enhances radio-sensitivity to conventional megavoltage
photon beam radiation (XRT) in multiple pediatric sar-
coma cell lines [7].
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to ionizing radiation. Cells have evolved mechanisms to
repair these lesions that are otherwise lethal. These
mechanisms involve phosphorylation of histone H2AX
(then called gH2AX) and the loading of repair proteins
on the chromatin adjacent to the DSBs. It has also been
shown that the chromatin architecture in the region sur-
rounding the DSB has a critical impact on the ability of
cells to mount an effective DNA damage response [11].
As SAHA is known to modify chromatin structure, we
investigated the changes in gH2AX-expression after irra-
diation and were able to find a correlation of increased
radiosensitivity with increased gH2AX-expression as
well as prolongation of radiation-induced gH2AX-
expression in the sarcoma cell lines, but interestingly
n o ti nn o r m a lt i s s u ec e l ll i n e sw h e nS A H Aw a sc o m -
bined with XRT [C. Blattmann, submitted]. As DSBs are
known to occur with a higher frequency in response to
heavy ions compared to photon irradiation [12] we now
were interested in the combination of heavy ion radia-
tion with HDACIs.
Heavy ion therapy (HIT) with carbon ions has
achieved superior cancer control in tumors with other-
wise low radiosensitivity, like sarcomas [13]. Several evi-
dent as well as potential advantages over XRT have lead
to a wider popularization of HIT with a number of new
facilities that have become operational worldwide. First
in vitro data show promising effects by the combination
of HIT and SAHA in esophageal cancer cells [14].
Here we investigate the effect of the HDACI SAHA in
combination with HIT on two pediatric sarcoma cell
lines (KHOS24-OS (osteosarcoma), A-204 (rhabdomyo-
sarcoma)), as well as a normal tissue cell line
(HFOB1.19, human osteoblast).
Materials and methods
Cell lines
Human sarcoma cell lines (KHOS24-OS and A-204), as
well as the human osteoblast hFOB 1.19 were obtained
from the American Type Culture Collection (ATCC;
Rockville, MD).
Chemicals
SAHA was obtained from Alexis Biochemicals (Lörrach,
Germany). Primary monoclonal mouse antibodies
against Rad51, Ku70 and Ku80, p21 and p53 were
obtained from Abcam (Cambridge, UK). Primary mono-
clonal mouse antibodies against ß-actin as well as a sec-
ondary antibody for immunoblot experiments were
purchased from CellSignaling Technology (Danvers,
MA, USA). For the flow cytometry experiments as well
as immunoblots, gH2AX antibody Alexa Fluor
® 488
anti-H2A.X-phosphorylated (Ser139) was obtained from
BioLegend (San Diego, USA).
Clonogenic assay
Clonogenic assays were performed as described pre-
viously [7]. In brief, exponentially growing tumor cells
were plated in T25 culture bottles at appropriate num-
bers to give an estimated 50-250 colonies/flask and were
incubated with medium containing 0 to 5 μMS A H A .
Incubation of SAHA with the respective LD20 and LD50
for each cell line started 24 h before XRT/HIT. Incuba-
tion was stopped after 5 days. Monolayers were stained
with 0.5% crystal violet for 10 minutes. Plates were
stained with 0.1 M sodium citrate (pH 4) in ethanol
100% (3:1) for another 10 minutes. Afterwards, plates
were dried for 48 to 72 h and colonies were counted
manually. Survival was defined as the ability of cells to
form colonies (≥ 50 cells).
Surviving fractions were obtained by normalizing the
plating efficiencies (cell number/plated cell) to the
respective control values. Each experiment was done in
triplicate and at least three independent repetitions were
performed. In combination experiments, the survival
rates after different doses of radiation were normalized
to the treatment with SAHA given alone.
Following a theoretical concept of combination effects
by Steel and Peckham [15,16] the range of additivity was
calculated from the response to the LD 20 of the single
agent. This range is encompassed by the prediction of
independent cell killing (accounted for by normalizing
the radiation survival rates to SAHA toxicity, see above)
and a theoretical survival curve that can be obtained if
the fraction of cells surviving drug treatment is formally
treated as being irradiated with an isoeffective dose D¢.
Assuming that the radiation sensitivity coefficients were
ax and bx, one readily finds that the theoretical survival
curve (normalized to drug toxicity) can be written as SF
=e x p ( -apD-b x D2) with a p = ax + 2bxD¢. For gra-
phical representation of the combination effect in excess
of independent cell killing, both the experimental survi-
val fraction (cell number/plated cells) and the fitted sur-
vival curves were multiplied with the averaged surviving
fraction after SAHA exposure alone.
Flow cytometric analysis of gH2AX-expression, cell cycle
and apoptosis
Cells were seeded in T25 culture plates at a density of 1
×1 0
6 cells per plate 24 h before HIT. In the SAHA
experiments, 0.5-1 μMS A H Aw a sa d d e d2 4hb e f o r e
HIT. At certain time points after HIT, cells were har-
vested and centrifuged (800 g). Cells were washed with
PBS several times and then fixed with 3% paraformalde-
hyde (PFA, Sigma) for 10 min at room temperature
(RT). Ice-cold methanol (90%) was added and samples
were kept on ice for another 30 min. Afterwards, sam-
ples were washed three times in 0.5% BSA/PBS re-sus-
pended in 100 μl0 . 5 %B S A / P B Sa n di n c u b a t e df o r1 0
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by 1 h incubation at RT in 10 μl antibody plus 90 μl
0.5% BSA/PBS per sample. Finally, cells were washed
three times with 0.5% BSA/PBS. Cells were further
stained with DAPI for cell cycle analysis for 30 min at
R Ta n da n a l y z e ds i m u l t a n e o u s l yw i t ht h egH2AX stain-
ing. The samples were analyzed directly on a “Galaxy
Pro"- Flowcytometer from Partec (Münster, Germany).
The relative fluorescence intensity in the gated areas
was calculated using the multiparameter “Flow max”
software from Partec as described in a further report.
For the detection of apoptotic cells we used Nicoletti
stain measured in a FACS Calibur Flow cytometer (Bec-
ton Dickinson Cytometry Systems, San Jose, CA) as
described in our earlier report [7].
To assess the mean extent of DNA damage at a parti-
cular phase of the cell cycle, the mean values of gH2AX
immunfluorescence were calculated separately for G0/1,S
and G2/M cells by the computer-interactive “gating” ana-
lysis. Cells in S and G2/M have 1.5 and 2.0 times higher
gH2AX mean immunofluorescence respectively, com-
pared to cells in G0/1 because of the increase of DNA and
histone content during the cell cycle. Therefore, the data
has to be normalized for DNA (histone) content by divid-
ing the mean gH2AX immunofluorescence of S- and G2/
M-phase cells by 1.5 and 2.0, respectively. Finally, a low
level of gH2AX immunofluorescence is seen in the
untreated cells which represent an “intrinsic” gH2AX
phosphorylation. Therefore, the gH2AX immunofluores-
cence level of the untreated controls has to be subtracted
from the immunofluorescence level of the treated cells in
order to get the gH2AX immunofluorescence level which
is treatment-related. Then multiparametric analysis was
done on a Galaxy pro flow cytometer (PARTEC, Mün-
ster, Germany) by stimulating the fluorochromes DAPI
with mercury 100 W vapour lamp, H2AX-FITC with a
488 nm air cooled argon laser and measuring the fluores-
cence intensities at 530/30 nm and apoptotic cells stained
with Nicoletti stain/DAPI/propidium iodide (PI) at 610/
20 nm. The green fluorescent FITC, and red fluorescent
PI, was measured in the logarithmic mode, DAPI stained
DNA measured in linear mode. Analysis and calculation
the Flow Max software (Partec, Münster, Germany was
used. Each analysis represents 5000 cells.
Immunoblot analysis
Immunoblot analysis was performed as reported pre-
viously [7]. In brief, following treatment, cells were lysed
with lysis buffer (0.5 M tris/Cl, pH 6,8, SDS, 87% Gly-
cerin, DTT 1 M ad Aqua 100 ml). Following this, 1 ml
lysate was incubated with 1 μlb e n z o n a s ef o r1 5m i na t
37°C. 40 μg of protein extracts underwent electrophor-
esis onto a 12% polyacrylamide gel (Pierce Biotechnol-
ogy Inc., Roxford, IL, USA) under reducing conditions.
The separated proteins were transferred onto nitrocellu-
lose membranes (Amersham Pharmacia Bioscience, Pis-
cataway, NJ). The membranes were then incubated for
45 minutes in blocking buffer (tris-buffered saline with
0.1% Tween (TBS-T) and 5% nonfat dry milk), followed
by incubation with specific primary antibodies at 1:1000
dilution at -4°C for 24 h or at room temperature for 1
h. After being washed with TBS-T buffer three times,
the membrane was incubated with anti-mouse IgG sec-
ondary antibody (Cell Signaling Technology, Danvers,
MA, USA) at 1:1000 dilution for 1 h at room tempera-
ture. The signals were visualized with the ECL+ detec-
tion system and autoradiography.
Confocal Laser Scanning Microscopy
The nuclear organization of chromatin and gHSAX in
KHOS-24 OS cells upon treatment with SAHA, HIT
and both in combination was observed by laser scanning
microscopy using a Zeiss LSM 700, equipped with a 63
× oil objective. Images were acquired with pinhole-size
1 Airy at pixel-size 100 nm. Cells were fixed with buf-
fered 2% formaldehyde, chromatin stained with DAPI
and gH2AX revealed by IHC using Alexa 488-charged
secondary antibody as reporter.
Statistical analysis
All experiments were performed at least twice. Further-
more, each experiment was done in duplicate. Clono-
genic assays were performed in triplicate. Combination
studies were evaluated using student’s t test with the
resulting p value representing a two-sided test of statisti-
cal significance.
Results
We determined the survival of the two sarcoma cell
lines (KHOS-24OS and A-204) as well as a human cell
line (hfOB 1.19) exposed to combination therapy of
SAHA and HIT using clonogenic assays. The cell lines
were pretreated with 0.25 and 0.5 μM SAHA for A-204,
a n d0 . 5a n d1μM SAHA for KHOS-24OS as well as
hFOB1.19 24 h before HIT. The SAHA concentrations
correspond well to clinically achievable plasma concen-
trations shown in phase I studies of SAHA in adult
patients [16] and represent the LD20 and LD50 for the
cells as shown in Figure 1.
Figure 2 shows that HIT alone suppressed the clono-
g e n i cs u r v i v a ls i g n i f i c a n t l ym o r et h a nX R Ta l o n ei na l l
three cell lines. The combination with SAHA suppressed
the clonogenic survival after radiation with carbon ions
significantly more in both pediatric sarcoma cell lines
investigated with a stronger effect in KHOS-24OS. The
effect of SAHA in combination with heavy ions for
KHOS-24OS as well as A.-204 was clearly supra-additive
as shown in Figure 3. Interestingly, in contrast SAHA
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tion with HIT in the human osteoblast cell line (Figure
4); a tendency we also observed in combination with
XRT (not significant) [7].
We further evaluated gH2AX-expression (Figure 5)
which has been established as a sensitive indicator of
DSB [17], choosing radiation doses of the respective
LD80-90 of the sarcoma cell lines. Treatment with
SAHA alone had no effect on gH2AX-expression in all
cell lines compared to the untreated controls. Just like
XRT, HIT resulted in a peak and a following continuous
time-dependent drop of mean immunofluorescence (IF)
of gH2AX-positive cells in both sarcoma cell lines. Pre-
treatment with SAHA significantly increased the effect
of HIT in KHOS-24OS as well as A-204. In the XRT,
but even more in the HIT experiments, the KHOS-
2 4 O Sc e l ll i n es h o w e dap r o l o n g e dp r e s e n c eo fgH2AX,
respectively DSB, which was not observed in A-204. In
contrast to KHOS-24OS, differences in gH2AX-expres-
sion after HIT as well as XRT disappeared 6 h after
treatment in the A-204 cell line. With hfOB1.19, corre-
sponding with the results of the clonogenic assays, pre-
treatment with SAHA reduced the gH2AX induction
caused by XRT or HIT, emphasizing the suggested
radio-protective effect of SAHA in the normal tissue cell
line.
To confirm our results, we investigated the gH2AX-
expression using immunoblot technique. The findings
showed that gH2AX-expression was significantly
Figure 1 Clonogenic Survival after SAHA Treatment.
Suberoylanilide hydroxamic acid (SAHA) decreases clonogenic
survival in pediatric sarcoma cell lines (KHOS-24OS, A-204) as well as
an osteoblast cell line (hFOB 1.19) in a dose-dependent manner.
Figure 2 Clonogenic Survival after Radiation +/- SAHA
Treatment at LD50. Clonogenic survival of KHOS-24OS (a) and A-
204 (b) and hFOB1.19 (c) treated with different doses of
conventional photons (XRT) and carbon ions (HIT) with and without
the respective LD50 dose of SAHA for each cell line (added to the
medium 24 h prior to radiation).
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ment, compared to the untreated cells in KHOS-24OS,
as well as A-204, but not in hFOB1.19 (Figure 6).
In our earlier photon experiments we found, that
SAHA attenuated key proteins involved in the repair of
DSB [7]. Therefore, we again investigated the expression
of DNA-DSB repair proteins like Rad51, Ku70 and Ku80
in our HIT experiments. All these proteins play a criti-
cal role in the repair of DNA-DSB, and are known to be
activated by, amongst others, gH2AX [18]. However, in
contrast to our XRT experiments, SAHA did influence
expression of either, Rad51, Ku70 and Ku80 measured
24 h after HIT only in the KHOS-24OS, but not in the
A-204 cell line when added to the cell culture 24 h
before radiation. There was also no change in expression
of p53 observable after HIT, SAHA or the combination
in all cell lines. However, there were changes in p21
expression. After treatment with SAHA or SAHA plus
HIT, p21 was up-regulated in the two sarcoma cell
lines, but down-regulated in the osteoblast cell line,
compared to the untreated controls and HIT only treat-
ment, respectively (Figure 6). This finding suggests that
changes in DNA-repair are less relevant, but that cell
cycle regulation changes and a p53-independent apopto-
tic pathway are the major mechanisms for the sensitiza-
tion to HIT by SAHA. We further assessed apoptosis 24
and 48 h after HIT. Apoptosis was indeed increased in
the KHOS-24OS and A-204 cell line, but rather
decreased in the osteoblast cell line 48 h (Figure 7) after
irradiation.
Cell cycle observations (Figure 8) of KHOS-24OS
revealed a shift into G0/1 arrest caused by SAHA,
whereas the combination treatment resulted rather in a
shift towards G2/M arrest with increasing doses of HIT.
In A-204, the shift towards G0/1 arrest caused by SAHA
was comparably insignificant. The combination treat-
ment of HIT and SAHA resulted in a slight G2/M shift
and a total loss of cells in S-phase. In the hFOB1.19 cell
line, SAHA also resulted in a slight increase of cells in
G0/1 phase, but HIT only, as well as the combination
Figure 3 Survival of sarcoma cells after Radiation +/- SAHA
Treatment at LD20. Survival of KHOS-24OS and A-204 cells treated
with different doses of radiation given alone. (open symbols) or in
combination with the LD20 of SAHA for each cell line (closed
symbols). The data are mean values (and standard deviations) from
three independent determinations for each treatment modality. The
survival data after combined treatment are normalized to SAHA
toxicity alone. The curves represent fits of the linear-quadratic
survival expression to the respective data. The slashed lines show
the calculated expectation for each modality revealing a supra-
additive effect in the real measurements (solid lines).
Figure 4 Survival of Osteoblast Cell line after Radiation +/-
SAHA Treatment at LD20. Survival of hFOB 1.19 cells treated with
different doses of radiation given alone (open symbol) or in
combination with the LD20 of SAHA (closed symbol). The data are
mean values (and standard deviations) from three independent
determinations for each treatment modality. The survival data after
combined treatment are normalized to SAHA toxicity alone. The
curves represent fits of the linear-quadratic survival expression to
the respective data. The slashed lines show the calculated
expectation for each modality revealing no additivity, but rather a
protective effect in the real measurements (solid lines) in hFOB 1.19.
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trast, rather a decrease of cells in G0/1 in favor of an
increased number of cells in S-phase was observed.
Microscopic inspection of chromatin and gH2AX in
KHOS-24OS cells after treatment with SAHA only, HIT
only as well as in combination (Figure 9) revealed abun-
dant focal accumulations of gH2AX after HIT alone as
well as in combination with SAHA, especially 30 min
after HIT-exposure and significantly reduced after 24 h.
No significant trend-setting differences were observable
after HIT only compared to combination treatment with
HIT and SAHA in this cell line. Chromatin showed de-
compaction 30 min after SAHA exposure as expected.
This effect began to reverse within 24 h after treatment.
Figure 5 gH2AX-expression after XRT and HIT. gH2AX-expression of KHOS-24OS, A-204 and hFOB 30 min, 2 h, 6 h and 24 h after XRT (a) and
HIT (b) with and without prior incubation with SAHA as measured by flow cytometry.
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HDACI have been reported to prevent radiation-induced
toxicity on normal tissue after XRT [19], while sensitiz-
ing tumor cells [7,20,21]. We are the first to show a pro-
mising, even selective effect by the combination of HIT
and HDACI in infantile sarcoma cells.
We have previously reported on the ability of the
HDACI SAHA to selectively radio-sensitize pediatric
sarcoma cell lines to photon treatment as opposed to
normal tissue cell lines [7] suggesting a therapeutic ben-
efit by this combination. HIT is a further promising
alternative to XRT in otherwise often radio-resistant sar-
comas due to the superb biological effectiveness and
dose conformity. However, the potential of heavy ions
to cause adverse late effects such as secondary cancer
must not be overlooked, especially in young and pedia-
tric patients. Clinical studies are underway [13]. Despite
the favorable clinical outcome of HIT alone, the interest
in combination treatments, especially substances that
ameliorate heavy ion-induced damage to normal cells, is
increasing. Therefore the combination of HIT with
molecularly targeted approaches like the combination
with HDACI is worth investigating.
Apoptosis, necrosis, autophagy and delayed reproduc-
tive death of progeny cells are possible mechanisms for
cell death after HIT. Further possible effects of HIT are
C            S       HIT    HIT+S
A-204
KHOS-24OS
hFOB 1.19
C 9 S          HIT    HIT+S
JH2AX
p21
ß-Actin
JH2AX
p21
ß-Actin
JH2AX
p21
ß-Actin
C           S      HIT     HIT+S
Figure 6 Immunoblot analyis of gH2AX and p21. gH2AX-
expression measured immunhistochemically 2 hours after HIT and
p21 expression in KHOS-24OS, A-204 and HFOB1.19 treated with
vehicle control (C), 0,5 (A-204)-1 μM (KHOS-24OS and HFOB1.19)
SAHA and HIT (cell specific doses, see Figure 9) or the combination
of SAHA and HIT 24 h after HIT.
Figure 7 Apoptosis measured via FACS after HIT +/- SAHA.
Apoptosis of KHOS-24OS (7), A-204(8) and HFOB1.19(9) measured
via flow cytometry according to Nicoletti after HIT irradiation with 6
Gy (a), 4 Gy (b) and 4 Gy (c). SAHA was added 24 h before
irradiation. Apoptosis was measured 48 h after irradiation.
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accelerated differentiation. Previous studies have shown
that changes in chromatin organization, as induced by
HDACI, modify cell morphology and de-condensate
chromatin, which seems to interrelate with cellular
radio-sensitivity [22]. Changes in cellular ultrastructure
and increased autophagic vacuoles have been observed
after heavy-ion exposure [23]. In consequence of these
reports, we hoped to find further hints towards the
underlying mechanism of HDACI-induced changes in
sensitivity to HIT by microscopy. We observed KHOS-
24OS after SAHA alone, combination treatment with
HIT and SAHA and HIT only. However, no trend-set-
ting differences in cell morphology were observable.
In contrast to our previous findings concerning the
combination of XRT and SAHA in the three cell lines
investigated [7], repair protein expression was not influ-
enced by the combination of SAHA and HIT in A-204,
but only in KHOS-24OS. It has previously been reported
that high-LET radiation induces different changes in
gene expression as compared to low-LET XRT a possi-
ble explanation for this discrepancy [24]; However, the
combination of SAHA with either XRT or HIT showed
similar effects on the repair kinetics of DSB as measured
by gH2AX, despite the different reaction on the protein
expression level immediately after treatment.
The fact that HDACI enhance radio-response to XRT
of human tumor cells by impairing the repair of DNA
damage has been reported earlier [22,23]. Our data
show that this is also true for our infantile sarcoma cell
lines and the combination with HIT. As shown by
Hamada et al., gH2AX focus disappearance, i.e. DNA-
repair, proved to be significantly slower after treatment
with high-LET HIT than with XRT in both sarcoma cell
lines, as well as the osteoblast cell line [25]. SAHA
increased this effect in the sarcoma cell lines, but
showed a protective effect on the osteoblast cell line.
The significantly decreased number of DSB in the osteo-
blast cell lines after combination treatment with SAHA
and HIT compared to HIT only substantiates the hope
that SAHA increases the therapeutic ratio. This is con-
sistent with our earlier results, as well as many other
reports that showed the ability of HDACI to prevent
radiation-induced toxicity on normal tissue after XRT
[7,17],
We deliberately chose two infantile sarcoma cell lines
with differing properties for our experiments. KHOS-
2 4 O Si sat e t r a p l o i do s t e o s a r c o m ac e l ll i n ew i t ha
known p53 mutation, A-204 a diploid and tetraploid
rhabdomyosarcoma cell line with wild-type p53.
KHOS-24OS showed a lower sensitivity to XRT radia-
tion compared to A-204 [7], which is in line to the
mutated p53. Multiple pathways are involved in main-
taining the genetic integrity of a cell after exposure to
ionizing radiation. A common cellular response to DNA
damaging agents is the activation of cell cycle check-
points. One of the key proteins in the checkpoint path-
ways is the tumor suppressor gene p53, which is
frequently damaged in tumor cells and mediates the two
major DNA damage-dependent cellular checkpoints at
the G(1)-S transition and at the G(2)-M transition [25].
p53 mutations often lead to XRT resistance [26]. While
KHOS-24OS contains mutated p53, A-204 is a p53-wild
Figure 8 Cell cycle analysis after HIT +/- SAHA. Cell cycle
analysis in KHOS-24OS (10), A-204 (11) and HFOB1.19 (12) after
treatment with HIT +/- SAHA.
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heavy ions has previously been shown to be less depen-
dent on the cellular p53 status, resulting in a lower
radiobiological effectiveness (RBE) in those cells that are
more sensitive to photon treatment due to p53-depen-
dent apoptosis [28]. HDAC inhibitors are also known to
enhance mechanisms leading to apoptosis independently
from the p53 status [29].
 
Control        30 minutes            24 hours 
SAHA 1μM    30 minutes          24 hours 
 
3 Gy HIT      30 minutes                   24 hours 
3 Gy HIT +     30 minutes                  24 hours 
1μM SAHA 
Figure 9 Confocal laser scanning microscopy of KHOS-24OS. Concocal laser scanning microscopy after staining with fluorescence markers
towards chromatin (DAPI) and gH2AX. Cells were analyzed 30 min and 24 h after treatment with 1 μM SAHA, 3 Gy HIT and the combination of
both.
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XRT has a stronger effect in KHOS-24OS than in A-204
cells. However, HIT and SAHA are promising in A-204
as well, and the synergistic effect of HIT and SAHA was
altogether only a little more pronounced in the p53
mutated cell line KHOS-24OS. Radio-sensitization to
HIT by SAHA thus seems to be independent of p53, as
previously described for either single agent alone [30].
While p53 expression was not affected by SAHA, HIT
or the combination, p21 was up-regulated in the sar-
coma cell lines by SAHA as well as SAHA+HIT and
down-regulated in the osteoblast cell line, correlating
well to the observed apoptotic reactions of the sarcoma
cell lines in contrast to hFOB1.19. p21 is known to
influence cell proliferation, regulation of S-phase DNA-
replication, as well as DNA-repair. The observed ther-
apy-related changes in cell cycle progression may be
induced by p21 interaction. However, in contrast to
XRT, heavy ion irradiation is known to be effective at
killing cells with little cell-cycle dependency [31]. While
p21 does not by itself induce apoptosis, it does interact
with caspase-associated, p53-independent apoptotic
pathways [32].
Interestingly, however, the influence of the combina-
tion therapy of SAHA with HIT, as well as XRT on the
repair kinetics as represented by the gH2AX-response,
proved to be higher in A-204 than in KHOS-24OS (Fig-
ure 5). Here p53 may play a role after all. It has pre-
viously been reported, that p53 wild-type cancer cells
show a faster loss of gH2AX after XRT than cells with
p53 deficiency [33]. Our findings suggest that this is
also true for HIT, especially when combined with
SAHA. As suggested by Hamada et al., high-LET radia-
tion may be particularly effective in patients with
mutated p53 or p53 depleted tumors and the addition
of a HDACI may be of additional value [25]. p21 has
been demonstrated to be a predictive marker for
response to HDACI treatment alone in sarcomas [34].
Our findings warrant further investigations whether p21
status of sarcomas may serve as an additional prognostic
marker for the efficacy of combined HIT with HDACI.
Our study shows that SAHA is an intriguing novel
adjuvant to HIT in certain sarcomas.
Conclusion
The combination of HDACI like SAHA with HIT may
be a promising strategy in the treatment of infantile sar-
comas. Our data suggest an improvement of therapeutic
ratio.
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